Hence then, the article about dupixent dupilumab approved by european commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Dupixent® (dupilumab) Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe Atopic Dermatitis )
Last updated :
Also on site :
- Ukraine will try “to get some concessions” from Trump at meeting
- Getting hired in 2026 is all about your ‘microcredentials’ says CEO of $1.3 billion learning platform—this is what he tells Gen Z to focus on
- Teens arrested after large disturbance, multiple fights at Joliet mall